Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.
Gagne M, Flynn BJ, Honeycutt CC, Flebbe DR, Andrew SF, Provost SJ, McCormick L, Van Ry A, McCarthy E, Todd JM, Bao S, Teng IT, Marciano S, Rudich Y, Li C, Jain S, Wali B, Pessaint L, Dodson A, Cook A, Lewis MG, Andersen H, Zahradník J, Suthar MS, Nason MC, Foulds KE, Kwong PD, Roederer M, Schreiber G, Seder RA, Douek DC.
Gagne M, et al. Among authors: mccormick l.
Nat Commun. 2024 Aug 12;15(1):6894. doi: 10.1038/s41467-024-51046-w.
Nat Commun. 2024.
PMID: 39134521
Free PMC article.